The George Mason University, National Center for Biodefense and Infectious Diseases, within the College of Science, invites well-qualified candidates to apply for a Postdoctoral Research Fellow position in the area of virology working with RNA viruses. George Mason University has a strong institutional commitment to the achievement of excellence and diversity among its faculty and staff, and strongly encourages candidates to apply who will enrich Mason’s academic and culturally inclusive environment.
News
Recent News
10/20/2026
Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval
Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …
10/20/2026
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights …
10/16/2026
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company’s research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for the …